





Clinical science

Elicitation of expert prior opinion to design the BARJDM trial in juvenile dermatomyositis

Charalampia Papadopoulou ^{1,2,*}, Neil Martin³, Nadia Rafiq⁴, Liza McCann⁵, Giulia Varner ⁶, Kerstin Nott⁷, Sandrine Compeyrot-Lacassagne^{1,2}, Maria Leandro^{8,9}, Charlene Foley⁴, Kishore Warrior¹⁰, Nathan Green ¹¹, Mandy Wan^{4,12}, Hakim-Moulay Dehbi¹³, John Whitehead ¹⁴, Despina Eleftheriou^{1,2}, Paul Brogan^{1,2}

¹Paediatric Rheumatology Department, Great Ormond Street Hospital for Children, NHS Foundation Trust, London, UK

²Inflammation and Rheumatology Section, University College London Great Ormond Street Institute of Child Health, London, UK

³Paediatric Rheumatology Department, The Royal Hospital for Children, Glasgow, UK

⁴Paediatric Rheumatology Department, The Evelina London Children's Hospital, London, UK

⁵Paediatric Rheumatology Department, Alder Hey Children's Hospital, Liverpool, UK

⁶Paediatric Rheumatology Department, Royal Manchester Children's Hospital, Manchester, UK

⁷Paediatric Rheumatology Department, Southampton Children's Hospital, Southampton, UK

⁸Rheumatology Department, University College London Hospital, London, UK

⁹Centre for Rheumatology, University College London, London, UK

¹⁰Paediatric Rheumatology Department, Nottingham Children's Hospital, Nottingham, UK

¹¹Department of Statistical Science, UCL, London, UK

¹²Institute of Pharmaceutical Science, King's College London, London, UK

¹³Comprehensive Clinical Trials Unit, Institute of Clinical Trials and Methodology, UCL, London, UK

¹⁴Department of Mathematics and Statistics, Lancaster University, Lancaster, UK

*Correspondence to: Charalampia Papadopoulou, University College London Great Ormond Street Institute of Child Health, 30 Guilford Street, London WC1N 1EH, UK. E-mail: sejjcp6@ucl.ac.uk

Abstract

Objectives: To elicit and quantify expert opinion concerning the relative merits of two treatments for a rare inflammatory disease: JDM. The formal expression of expert opinion reported in this article will be used in a Bayesian analysis of a forthcoming randomized controlled trial known as BARJDM (baricitinib for JDM).

Methods: A Bayesian prior elicitation meeting was convened, following a previously described methodological template. Opinion was sought on the probability that a patient in the BARJDM trial would achieve clinically inactive disease, off glucocorticoids (GC) within a 12-month period with either MTX (standard of care); or baricitinib (a Janus kinase inhibitor, JAKi), with GC schedules identical in both arms of the trial. Experts' views were discussed and refined following presentation and further discussion of summated published data regarding efficacy of MTX or JAKi for JDM.

Results: Ten UK paediatric rheumatology consultants (including one adolescent paediatric rheumatologist) participated in the elicitation meeting. All had expertise in JDM, leading active National Health Service clinics for this disease. Consensus expert prior opinion was that the most likely probability of clinically inactive disease off GC within 12 months was 0.55 on baricitinib and 0.23 on MTX, with a greater degree of uncertainty for baricitinib.

Conclusion: Experts currently think that baricitinib is superior to MTX for the treatment of JDM, although there is uncertainty around this. BARJDM will therefore integrate randomized trial data with this expert prior opinion to derive a posterior distribution for the relative efficacy of baricitinib compared with MTX.

Keywords: JDM, Bayesian trial, prior expert opinion, MTX, baricitinib, BARJDM.

Rheumatology key messages

- Experts currently believe that baricitinib is more efficacious than MTX for JDM.
- Prior opinion can be integrated with randomized data to estimate treatment efficacy in Bayesian trials.
- Such Bayesian clinical trials can maximize learning from small clinical trials in rare diseases.

Received: 27 March 2024. Accepted: 8 July 2024

© The Author(s) 2024. Published by Oxford University Press on behalf of the British Society for Rheumatology.

This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<https://creativecommons.org/licenses/by/4.0/>), which permits unrestricted reuse, distribution, and reproduction in any medium, provided the original work is properly cited.

Introduction

Childhood-onset or juvenile idiopathic inflammatory myopathies (JIIMs) encompass a number of rare yet severe conditions affecting children and young individuals, primarily impacting muscles and skin but potentially involving various organs such as lungs, gut, joints, heart and the central nervous system [1]. The reported incidence ranges between 1.6 and 4.0 cases per million children per year [2]; the estimated prevalence is 2.5 cases per 100 000 children [2], mainly comprised of JDM, seen in over 85% of JIIM cases [3, 4]. Although JDM mortality has decreased globally and is often below 4% [5–7], certain cohorts still exhibit higher mortality rates of 5–8% [8–10]. Over the years, the focus has shifted towards assessing long-term functional outcomes, morbidity and health-related quality of life. The risk of disease damage increases linearly with time since diagnosis, emphasizing the need for early disease control with targeted treatment [11]. Up to 41% of patients experience functional impairment, leading to increased pain and decreased quality of life [6, 7, 9, 10, 12–14]. Children may face growth impairment or delayed puberty, particularly if the active phase of the disease occurs during early puberty. In adulthood, individuals with a history of JDM may still have active myositis requiring continuing immunosuppressive medication [15]. Additionally, JDM is linked to long-term risk of cardiovascular, pulmonary or cerebrovascular diseases [16, 17].

The rarity of JDM has resulted in a lack of randomized controlled clinical trials (RCTs). An international multicentre randomized trial established MTX combined with glucocorticoids (GC) as standard of care [18]. This trial took many years to conduct and needed 54 centres in 22 countries to recruit 139 newly diagnosed JDM patients. Randomization was to one of three different treatments: prednisone alone; prednisone in combination with ciclosporin or prednisone plus MTX. The results were most favourable for the MTX group, which is now accepted as standard of care [18–20]. However, only 26% of patients achieved clinically inactive disease after 12 months of treatment with GC and MTX [18]. Furthermore, responders experienced a lengthy median time to clinical remission (41.9 months), and concerns about GC toxicity persisted since MTX had only a limited steroid sparing effect.

There is, therefore, a clear need for better treatments for JDM. However, high-level evidence regarding the efficacy and safety of new medications primarily derived from case reports or case series [21]. Several clinical trials are currently underway to assess the safety and effectiveness of JAK inhibitors (JAKi) in adults with treatment-resistant myositis [22, 23]. For paediatric patients, there are only retrospective and uncontrolled reports of JAKi use for JDM. These suggest good clinical efficacy and safety and also provide indications that JAKi may target JDM at an immunopathogenic level, with downregulation of IFN biomarkers: normalization of whole blood IFN1 gene signature, and reduction of STAT1 phosphorylation in T cells and monocytes down to healthy control levels [24–26]. These initial observations suggest that JAKi could be an effective and better-targeted treatment for JDM, but no RCT data are available to date.

An RCT leading to a definitive conclusion is infeasible in the UK since too few JDM patients are likely to be available to provide adequate power. For example, a 1:1 randomized trial with power 0.90 to detect an efficacy odds ratio of 2.0 (a

reasonable superiority effect size) using a two-sided significance level of 0.05 would require 416 patients (208 per treatment arm). This number would take several decades to recruit in the UK and would be extremely challenging even for an international study.

To provide some quantification of the relative efficacy of MTX (standard of care) vs. the JAKi baricitinib, the consensus opinion of their relative merits was elicited from 10 expert clinicians. This is to be used in the Bayesian analysis of a forthcoming prospective randomized comparison of the two treatments (BARJDM: baricitinib for JDM). This article gives an account of how the expert prior opinion we derived for BARJDM was elicited, using our previously described methodological template [27].

Materials and methods

BARJDM trial synopsis

BARJDM is a multicentre, open label, randomized, controlled, superiority trial to assess the effectiveness and safety of baricitinib in combination with GC for the treatment of newly diagnosed JDM, and is currently in set up. The trial will employ Bayesian methodology for the primary end point analysis and will combine the evidence obtained from the patients treated with prior opinion elicited from 10 UK experts. BARJDM will enrol 30 newly diagnosed JDM patients across 5–6 UK centres. Patients will be treated for 12 months, with 10 patients receiving MTX (standard treatment) and 20 patients receiving baricitinib. Patients in both treatment arms will receive the same protocolled GC regimen, weaning off by 6 months. Patient progress will be assessed at 3 and 6 months, with the option of increasing the baricitinib dose at these time points if there is an inadequate improvement according to protocolled definitions. Non-mandated rescue treatments can be used if clinically required, following local standards of care. The primary end point of the trial will be the percentage of patients with inactive disease, off GC, at 12 months (Table 1).

Identifying and inviting clinical experts

A face-to-face meeting of UK JDM experts was convened on 29–30 August 2023 at UCL, London, UK. An expert was defined as a paediatric or adolescent rheumatology consultant practicing in the UK, with an interest in and experience of looking after children and young people with JDM evidenced by having seen on average of at least one new case per year throughout their practise; and active participation or leadership of a National Health Service clinical service managing patients with JDM. Invitations were sent to their professional email addresses found through the Juvenile Cohort and Biomarker Study (JDCBS) [5] and through the national JDM topic specific group (TSG) of the Clinical Studies Group. Initial expressions of interest were received from 16 eligible respondents, of whom (for logistical reasons) 10 were able to attend the face-to-face meeting. The expert group comprised the following co-authors of this article: N.M., N.R., L.M., G.V., K.N., S.L., C.F., M.L., C.P., K.W., C.P., K.W. They came from across the UK (see author affiliations). All participants volunteered to take part in the prior elicitation meeting as experts. No patients were involved in the meeting. Ethics approval was therefore not required.

Table 1. The baricitinib for JDM (BARJDM) trial design

Hypothesis	Oral baricitinib combined with glucocorticoids is superior to subcutaneous MTX combined with glucocorticoids for the treatment of newly diagnosed JDM
Entry criteria	Newly diagnosed, treatment naïve ^a JDM patients (≤ 17 years of age) who meet EULAR/ACR classification criteria for dermatomyositis
Randomization and sample size	2:1 baricitinib ($n = 20$): MTX ($n = 10$); 30 patients total
Control (MTX) treatment arm	MTX dose: 15 mg/m ² subcutaneously once a week
Experimental (baricitinib) treatment arm	1) Baricitinib starting dose, all patients: ≥ 6 years: 4 mg once a day; < 6 years: 2 mg once a day. 2) Dose increases ^c permitted at 3 or 6 months if lack of clinical response (defined according to protocol)
Glucocorticoid regimen	1) Same for both arms of the trial: prednisolone 2 mg/kg/day, weaning off completely by 6 months according to a protocol 2) Up to three doses of high dose intravenous methylprednisolone (30 mg/kg/dose) are permitted after randomization
Primary end point	Percentage achieving clinically inactive disease ^b , and off glucocorticoids at 12 months
Rescue treatment (non-mandatory)	1) At any stage of the study, all patients who develop clinical deterioration can receive rescue treatment as per treating physician decision 2) Receipt of rescue treatment will be deemed as treatment failure in terms of the primary end point analysis

^a Treatment naïve: patients who received prednisolone no higher than 1 mg/kg/day for up to 4 weeks can be included; patients who received IV methylprednisolone up to 30 mg/kg/day for 3 days prior to enrolment can be included; patients who have received MTX or baricitinib prior to enrolment will be excluded.

^b Clinically inactive disease is defined using modified PRINTO criteria: no active skin disease; creatine kinase (CK) ≤ 150 U/l; childhood myositis assessment scale (CMAS) $\geq 48/52$; Manual Muscle Testing 8 (MMT8) $\geq 78/80$; physician global assessment (PhyGLOVAS) $\leq 0.2/10$ on a visual analogue scale.

^c Dose increased to that described for monogenetic interferonopathy (<https://www.england.nhs.uk/wp-content/uploads/2021/07/1930-Baricitinib-policy-Final-1.pdf>).

Selection of the specific quantities to be elicited

Expert opinion was sought on the probability that a patient satisfying the entry criteria for BARJDM (newly diagnosed, treatment naïve) would succeed according to the primary end point: clinically inactive disease, off GC at 12 months. The probability of success for a patient treated with MTX was denoted by p_C , and expert views on the value of p_C were elicited directly. The corresponding probability of successful treatment with baricitinib was denoted by p_E , the value of which was derived indirectly from expert clinicians using questions about the relative merits of the two drugs, as previously described [27, 28]. Note that the application in these earlier articles was to a study seeking to demonstrate the non-inferiority of a study drug, whereas here the objective is to find evidence of superiority. This means that the mathematical details here differed slightly from those reported earlier, being easier to work through.

Mathematical modelling of beliefs and uncertainties

Expert opinions were elicited using the questionnaire shown in Table 2. Opinions regarding the value of p_C were determined by two parameters aimed at capturing the experts' preferences for the most probable p_C value and their associated uncertainty levels. These values were sought by asking the experts two questions (Q1 and Q2). The relative efficacy of MTX and baricitinib was expressed in terms of the odds ratio (OR) and the log-odds ratio ($\theta = \log_e \text{OR}$, the log being to base e, otherwise known as the natural log). The definition of OR and its implications for comparisons of p_E and p_C are shown in Fig. 1. The value of θ was modelled as a normal distribution, the parameters of which were determined by asking experts two questions (Q3 and Q4). From the resulting opinions about p_C and θ , a consistent opinion about p_E was derived. These two parameters were used as they could be treated as independent: experts' opinions about p_C and p_E would not be independent of one another and thus more difficult to elicit. To ensure that the elicited opinion truly reflected the experts' personal beliefs, two additional

Table 2. Establishing the BARJDM expert prior opinion

Response rate on MTX
Q1: I think the response rate on MTX will be 0 _____
Q2: I am 75% sure the response rate on MTX will be < 0 _____
Improvement due to baricitinib
Q3: I think that the odds ratio on response for baricitinib relative to MTX will exceed 1.0 with probability _____%
Q4: I think that the odds ratio on response for baricitinib relative to MTX will exceed 2.0 with probability _____%
Response rate on baricitinib (reworded 'sense-check' questions)
Q5: I think the response rate on baricitinib will be 0 _____
Q6: I am 75% sure the response rate on baricitinib will be < 0 _____
Definition of response: For the BARJDM trial a patient will be deemed to have responded if their disease is clinically inactive and they are off glucocorticoids at the assessment made 12 months after randomization to treatment; Q: question.

reworded 'sense-check' questions were posed (Q5 and Q6) and used informally in discussions. The calculation of the effective sample size (ESS) of a prior distribution proved particularly beneficial for clinicians in assessing their prior beliefs. This metric essentially provided clinicians with the hypothetical number of patients in a clinical trial needed to statistically yield the prior level of certainty being expressed for the parameters. Further details on these calculations and comparisons with alternative approaches can be found in [28].

The elicitation procedure followed an iterative approach, facilitated by mathematical models and customized computer software that enabled the generation of rapid and lucid graphical representations of density functions to facilitate discussion in real time. The presentation also included a demonstration of the outcomes resulting from the incorporation of hypothetical datasets to form posterior distributions. The computer program, developed in R using the Shiny package, was designed to offer a user-friendly and interactive interface, as detailed in earlier descriptions [27]. A testing phase involving two clinicians (P.B. and D.E.), who consequently did not




Figure 1. Definition and interpretation of odds ratios. For example, if the odds ratio is 2.00 and p_C equals 0.40, then p_E will be equal to 0.57. Notice that, for every odds ratio and every value of p_C , there is a value of p_E between 0 and 1

contribute their prior opinions during the actual meeting, led to refinements and adjustments before the formal meeting took place. The final software package we developed is freely available in editable format at: <https://egon.stats.ucl.ac.uk/projects/TrialExpertElicitation/>.

Training of the expert participants

Fig. 2 outlines the two-day meeting activities and their respective time allocations. Throughout the session, two statistical facilitators (J.W. and N.G.) supported the elicitation process. The meeting commenced with one of the statistical facilitators (J.W.) delivering a talk introducing Bayesian reasoning, credible intervals and the representation of treatment differences as log-odds ratios. This was followed by a practical exercise involving guessing the proportion of black blocks in a jar containing 60 pink and black blocks. The same exercise is described in [26]. It served as a rehearsal for the elicitation process and Bayesian methods in a neutral setting. Following the practical exercise, a talk was given summarizing the standard treatment options for JDM and providing an overview of the BARJDM trial.

Elicitation of opinions

Experts individually completed the structured questionnaire (Table 2), without discussion with any of the other experts. Each expert then discussed their answers privately with one of the statistical facilitators. The latter used the R program to visualize answers and guide each expert to adjust their responses until satisfied that the final model represented their opinions.

Consensus prior distributions for θ and p_C were then sought in a plenary session of all experts. Rather than using automatic mathematical aggregation or multiple priors, each expert presented their finalized questionnaire responses. Lengthy discussions led to a first attempt at reaching a consensus. This group prior reflected greater uncertainty about the relative efficacy of the two treatment arms than the individual priors, taking account of the range of opinions expressed and being influenced by the ESS which demonstrated how precise prior opinions would be equivalent to information from very large clinical studies. Potential BARJDM study outcomes for 30 patients

were considered, and posterior distributions illustrated the relative impact of prior beliefs and data. After overnight reflection, a final provisional consensus was reached at the beginning of the second day.

Presentation of published outcomes on the use of JAK inhibitors in JDM and influence on the provisional prior opinion

After submitting their individual prior opinion results and agreeing on a provisional consensus opinion, on day 2 the experts were given an update on currently published studies regarding efficacy and safety of JAKi in juvenile IIM (summarized in Supplementary Table S1, available at *Rheumatology* online). This included an overview of efficacy of JAKi used in 176 JDM patients with refractory disease, with specific emphasis on the efficacy across different organ systems (muscles, skin and lungs). Prior distributions from the first day were then updated by the experts to derive a final consensus opinion (defined a priori as $\geq 80\%$ agreement) regarding the relative efficacy of MTX vs. baricitinib.

Opinion about the randomization allocation ratio that should be used in the trial was also sought; but views about the total sample size were not, since this number was considered fixed (at $n=30$) by a national feasibility exercise that had been conducted separately based on JDCBS figures informing recruitment projections over 36 months from each of six potentially recruiting sites (allowing for up to 30% recruitment failure rate; data not shown).

Results

Provisional expert opinion prior to presentation of published literature

The provisional expert prior opinion derived at the end of day 1 before the presentation of published results regarding the efficacy of JAKi is summarized in Table 3. This suggested a probability of response of 0.23 for MTX, compared with 0.41 for baricitinib, with an ESS of 30 patients (assuming 15 per treatment arm for this purpose).




Figure 2. BARJDM (baricitinib for JDM) prior opinion elicitation meeting

Final consensus opinion derived after presentation and discussion of published literature

The final consensus expert opinion reached at the end of day 2 is also summarized in [Table 3](#) and the corresponding distributions are displayed graphically in [Fig. 3](#). Experts modified their final responses in relation to the efficacy of baricitinib (but not MTX) after extensive discussion of the literature review findings ([Supplementary Table S1](#), available at *Rheumatology* online). In both the provisional and the final judgements, the probability of response to MTX was predicted to be 0.23, with 75% certainty that it will be <0.33 . Presentation and open discussion of the literature review ([Supplementary Table S1](#), available at *Rheumatology* online)

influenced the final consensus opinion concerning baricitinib. The probability of response on that treatment was finally estimated to be 0.55. There was 90% certainty that baricitinib is better than MTX, and 70% certainty that it is better to the extent that the odds ratio on success exceeds 2.0. This prior opinion carried the same weight (ESS) as observing 22 patients (11 per treatment arm), reflecting an understandable degree of uncertainty among experts regarding the use of baricitinib for JDM given the relatively limited evidence base.

Randomization allocation

Experts agreed unanimously that even though the consensus prior opinion favoured baricitinib for JDM, there was

Table 3. Provisional and final consensus prior opinions regarding response rates for MTX and baricitinib

	Provisional consensus opinion	Final consensus opinion (after discussion of literature review)
<i>Elicited values</i>		
Response rate on MTX (p_C) (Q1)	0.23	0.23
p_C 75th percentile (Q2)	0.33	0.33
P (odds ratio >1.0) (Q3)	87%	90%
P (odds ratio >2.0) (Q4)	60%	70%
<i>Derived values</i>		
Response rate on baricitinib (p_E)	0.41	0.55
Effective sample size	30	22
Agreement among 10 experts	100%	100%

Provisional consensus opinion (100% agreement) obtained at the end of day 1, prior to the presentation of published literature on the use of Janus kinase inhibitors is shown. On day 2, following presentation and discussion of the published literature (Supplementary Table S1, available at *Rheumatology* online), the final consensus expert prior opinion was derived, again with 100% agreement among the experts. p_C = probability of response to control treatment (MTX), odds ratio = (odds of response to baricitinib)/(odds of response to MTX), p_E = probability of response to experimental treatment (baricitinib).




Figure 3. Final consensus expert prior opinion regarding successful response rates (clinically inactive disease at 12 months and off glucocorticoids) for MTX or baricitinib in JDM. The final expert consensus prior opinion was that the most likely value for p_C was 0.23; 90% and 50% credibility intervals were (0.11, 0.45) and (0.19, 0.33), respectively. The prior for p_E is derived from those for p_C and θ . It had mode = 0.55; 90% and 50% credibility intervals were (0.18, 0.86) and (0.37, 0.69), respectively and carried the same weight as observing 22 patients, 11 per treatment arm. Bari: baricitinib

sufficient equipoise to warrant a randomized controlled trial design for BARJDM. Since much more is known about the use of MTX in JDM compared with baricitinib, a 2:1 baricitinib: MTX randomization allocation was proposed to the experts. This proposal was unanimously accepted.

Discussion

Conducting clinical trials in rare diseases are challenging due to difficulties recruiting adequate sample size to achieve

statistical power. Historically, this has been a major barrier in rare paediatric autoimmune diseases such as JDM. The BARJDM trial will therefore use a Bayesian approach to combine prior expert opinion with the results of our trial to formulate a final result. Such rare disease trial methodology has been used before in paediatric rheumatology [27], and unblocks an important barrier for testing novel JDM-targeted therapeutics. This approach is clearly not as high in the hierarchy of levels of evidence as a trial involving hundreds of patients but does still allow a worthwhile increment in clinically meaningful knowledge to be made. Moreover, the consensus opinion of our 10 experts that are given in this article represent a helpful guide, particularly for less experienced clinicians.

It took some practice for the experts to provide realistic answers to Q3 and Q4 of the questionnaire. Q3 was 'I think that the odds ratio on response for baricitinib relative to MTX will exceed 1.0 with probability _____%', and Q4 was the same but with 2.0 in place of 1.0. Once it was appreciated that the difference between the two answers (Q3–Q4) was the belief that the OR lay between 1.0 and 2.0, the questions became easier to address. First, it made it clear that the answer to Q3 had to be larger than that to Q4. Second, it indicated that if the difference was large then the opinion about the value of OR was relatively precise (pretty sure it lies between 1.0 and 2.0), whereas a small difference indicated substantial uncertainty about the relative merits of the two treatments. In the context of the meeting, the answers to Q3 were invariably close to 1. In further applications of this approach, it may be possible to improve the form of Q3 and Q4 to make them easier to answer.

Expert prior opinion exercises of the type reported here come with inherent limitations. Expert opinion is by its nature subjective, and in rare diseases will be expressed with substantial uncertainty. Heterogeneity among experts will lead to a consensus view that has even greater uncertainty than the individual opinions. Experts will face challenges in quantifying their subjective beliefs in a suitable mathematical form, and practice in Bayesian reasoning is therefore a crucial component of any expert prior opinion elicitation exercise [27, 29, 30].

We attempted to mitigate some of these inherent limitations by deriving expert opinion before and after presentation and discussion of the literature regarding treatment of JDM with MTX or JAKi. Unsurprisingly, this did influence the expert prior opinion regarding the use of baricitinib but had no impact on the prior beliefs regarding the efficacy of MTX for JDM (Table 3), since clinicians are much more familiar with the use of MTX for JDM than baricitinib. Although publication bias may influence experts to be overly optimistic regarding efficacy of a new treatment, we did observe a healthy and realistic degree of uncertainty regarding the relative efficacy of baricitinib for JDM, evidenced by the final result associated with an ESS of 22; and the relatively wide distribution regarding the probability of response for baricitinib compared with MTX depicted in Fig. 3.

In conclusion, we applied a previously used approach for derivation of expert prior opinion as part of a Bayesian RCT of baricitinib for JDM. Expert opinion was that baricitinib is likely to be more efficacious than MTX, but with a considerable degree of uncertainty. These prior distributions will be combined with trial data from BARJDM, to derive posterior distributions [31], reported with credible intervals and other

numerical and graphical summaries of the relative merits of the two treatments.

Supplementary material

Supplementary material is available at *Rheumatology* online.

Data availability

The data underlying this article are available in the article and in its online [supplementary material](#).

Funding

This work was (partly) funded by the NIHR Great Ormond Street Hospital Biomedical Research Centre. The views expressed are those of the author(s) and not necessarily those of the NHS, the NIHR or the Department of Health.

Disclosure statement: The expert meeting was funded by discretionary academic University funds held by PB, with no contribution from industry or any other party with a potential or perceived conflict of interest. PB has received lecturing/constancy fees from Novartis, SOBI and Roche (not related to this work).

Acknowledgements

We would like to thank all the patients and parents of children with JDM who took part in the three Patient and Public Involvement and Engagement focus group meetings, funded by the NIHR GOSH BRC Patient and Public Involvement and Engagement Small Grants Award 2021, between November 2021 and February 2022. Patients and families have been consulted from the earliest inception of BAR-JDM providing valuable insights on the trial design.

References

- Papadopoulou C, Chew C, Wilkinson MGL, McCann L, Wedderburn LR. Juvenile idiopathic inflammatory myositis: an update on pathophysiology and clinical care. *Nat Rev Rheumatol* 2023;19:343–62.
- Meyer A, Meyer N, Schaeffer M *et al.* Incidence and prevalence of inflammatory myopathies: a systematic review. *Rheumatology (Oxford)* 2015;54:50–63.
- Lundberg IE, Tjärnlund A, Bottai M *et al.*; International Myositis Classification Criteria Project Consortium, the Euromyositis Register, and the Juvenile Dermatomyositis Cohort Biomarker Study and Repository (UK and Ireland). 2017 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Adult and Juvenile Idiopathic Inflammatory Myopathies and Their Major Subgroups. *Arthritis Rheumatol* 2017;69:2271–82.
- Patel B, Khan N, Werth VP. Applicability of EULAR/ACR classification criteria for dermatomyositis to amyopathic disease. *J Am Acad Dermatol* 2018;79:77–83.e1.
- Martin N, Krol P, Smith S *et al.*; Juvenile Dermatomyositis Research Group. A national registry for juvenile dermatomyositis and other paediatric idiopathic inflammatory myopathies: 10 years' experience; the Juvenile Dermatomyositis National (UK and Ireland) Cohort Biomarker Study and Repository for Idiopathic Inflammatory Myopathies. *Rheumatology (Oxford)* 2011; 50:137–45.

- Ravelli A, Trail L, Ferrari C *et al.* Long-term outcome and prognostic factors of juvenile dermatomyositis: a multinational, multicenter study of 490 patients. *Arthritis Care Res (Hoboken)* 2010; 62:63–72.
- Huber AM, Lang B, LeBlanc CMA *et al.* Medium- and long-term functional outcomes in a multicenter cohort of children with juvenile dermatomyositis. *Arthritis Rheum* 2000;43:541–9.
- Okong'o LO, Esser M, Wilmshurst J, Scott C. Characteristics and outcome of children with juvenile dermatomyositis in Cape Town: a cross-sectional study. *Pediatr Rheumatol Online J* 2016;14:60.
- Sanner H, Gran JT, Sjaastad I, Flato B. Cumulative organ damage and prognostic factors in juvenile dermatomyositis: a cross-sectional study median 16.8 years after symptom onset. *Rheumatology (Oxford)* 2009;48:1541–7.
- Sharma A, Gupta A, Rawat A, Suri D, Singh S. Long-term outcome in children with juvenile dermatomyositis: a single-center study from north India. *Int J Rheum Dis* 2020;23:392–6.
- Tsatskan V, Aldous A, Serafi S *et al.* Long-term outcomes in Juvenile Myositis patients. *Semin Arthritis Rheum* 2020; 50:149–55.
- Rider LG, Lachenbruch PA, Monroe JB *et al.*; IMACS Group. Damage extent and predictors in adult and juvenile dermatomyositis and polymyositis as determined with the myositis damage index. *Arthritis Rheum* 2009;60:3425–35.
- Mathiesen P, Hegaard H, Herlin T *et al.* Long-term outcome in patients with juvenile dermatomyositis: a cross-sectional follow-up study. *Scand J Rheumatol* 2012;41:50–8.
- Apaz MT, Saad-Magalhães C, Pistorio A *et al.*; Paediatric Rheumatology International Trials Organisation. Health-related quality of life of patients with juvenile dermatomyositis: results from the Pediatric Rheumatology International Trials Organisation multinational quality of life cohort study. *Arthritis Rheum* 2009;61:509–17.
- Boros C, McCann L, Simou S *et al.*; JDM Cohort and Biomarker Study (JDCBS). Juvenile dermatomyositis: what comes next? Long-term outcomes in childhood myositis from a patient perspective. *Pediatr Rheumatol Online J* 2022;20:102.
- Papadopoulou C, Hong Y, Krol P *et al.* The vasculopathy of juvenile dermatomyositis: endothelial injury, hypercoagulability, and increased arterial stiffness. *Arthritis Rheumatol* 2021;73:1253–66.
- Silverberg JJ, Kwa L, Kwa MC, Laumann AE, Ardalan K. Cardiovascular and cerebrovascular comorbidities of juvenile dermatomyositis in US children: an analysis of the National Inpatient Sample. *Rheumatology (Oxford)* 2018;57:694–702.
- Ruperto N, Pistorio A, Oliveira S, Paediatric Rheumatology International Trials Organisation (PRINTO) *et al.* Prednisone versus prednisone plus ciclosporin versus prednisone plus methotrexate in new-onset juvenile dermatomyositis: a randomised trial. *Lancet* 2016;387:671–8.
- Bellutti Enders F, Bader-Meunier B, Baildam E *et al.* Consensus-based recommendations for the management of juvenile dermatomyositis. *Ann Rheum Dis* 2017;76:329–40.
- Dabbak I, Rodero MP, Aeschlimann FA *et al.* Efficacy and tolerance of corticosteroids and methotrexate in patients with juvenile dermatomyositis: a retrospective cohort study. *Rheumatology (Oxford)* 2022;61:4514–20.
- Doudouliaki T, Papadopoulou C, Deakin CT. Use of rescue therapy with IVIG or cyclophosphamide in juvenile myositis. *Curr Rheumatol Rep* 2021;23:24.
- Chen DY, Hsu PN, Tang CH *et al.* Tofacitinib in the treatment of moderate-to-severe rheumatoid arthritis: a cost-effectiveness analysis compared with adalimumab in Taiwan. *J Med Econ* 2019;22:777–87.
- Paik JJ, Casciola-Rosen L, Shin JY *et al.* Study of tofacitinib in refractory dermatomyositis: an open-label pilot study of ten patients. *Arthritis Rheumatol* 2021;73:858–65.
- Sabbagh S, Almeida de Jesus A, Hwang S *et al.* Treatment of anti-MDA5 autoantibody-positive juvenile dermatomyositis using tofacitinib. *Brain* 2019;142:e59.

25. Aeschlimann FA, Frémond M-L, Duffy D *et al.* A child with severe juvenile dermatomyositis treated with ruxolitinib. *Brain* 2018; 141:e80.
26. Papadopoulou C, Hong Y, Omoyinmi E, Brogan PA, Eleftheriou D. Janus kinase 1/2 inhibition with baricitinib in the treatment of juvenile dermatomyositis. *Brain* 2019;142:e8.
27. Hampson LV, Whitehead J, Eleftheriou D *et al.* Elicitation of expert prior opinion: application to the MYPAN trial in childhood polyarteritis nodosa. *PLoS One* 2015;10:e0120981.
28. Hampson LV, Whitehead J, Eleftheriou D, Brogan P. Bayesian methods for the design and interpretation of clinical trials in very rare diseases. *Stat Med* 2014;33:4186–201.
29. Ramanan AV, Hampson LV, Lythgoe H *et al.* Defining consensus opinion to develop randomised controlled trials in rare diseases using Bayesian design: an example of a proposed trial of adalimumab versus pamidronate for children with CNO/CRMO. *PLoS One* 2019;14:e0215739.
30. Desai Y, Jaki T, Beresford MW *et al.* Prior elicitation of the efficacy and tolerability of methotrexate and mycophenolate mofetil in juvenile localised scleroderma. *AMRC Open Res* 2021;3:20.
31. Brogan PA, Arch B, Hickey H *et al.* Mycophenolate mofetil versus cyclophosphamide for remission induction in childhood polyarteritis nodosa: an open-label, randomized, Bayesian noninferiority trial. *Arthritis Rheumatol* 2021;73:1673–82.

Are you using a treatment that addresses all 6 key manifestations of PsA?

The key clinical manifestations of PsA are joints, axial, skin, enthesitis, dactylitis and nails.¹



Joint relief in PsA:

68% of patients achieved **ACR50** with Cosentyx[®] (secukinumab) at **Year 1** (observed data)²

Results from ULTIMATE (N=166). The primary endpoint of GLOESS mean change from baseline vs placebo at Week 12 was met (-9 vs -6, p=0.004)^{2,3}



Skin clearance in PsO:

55% of patients achieved **PASI100** at **Week 52** with Cosentyx 300 mg AI (secondary endpoint, observed data, N=41)⁴

Results from MATURE. The co-primary endpoints PASI 75 and IGA mod 2011 0/1 at Week 12 were met for Cosentyx 300 mg (N=41) vs placebo (N=40), (95% vs 10% and 76% vs 8% respectively, p<0.0001)⁴



Axial joint relief in PsA:

69% of patients achieved **ASAS40** at **Week 52** with Cosentyx 300 mg (secondary endpoint, observed data, N=139)¹

Results from MAXIMISE. The primary endpoint of ASAS20 with Cosentyx 300 mg (N=164) vs placebo (N=164) at Week 12 was met (63% vs 31% respectively, p<0.0001)¹



Click here to visit our HCP portal and learn more

Cosentyx is the first and only, fully human biologic that directly blocks IL-17A regardless of its source⁵⁻¹⁰



8 years

A consistent safety profile with over 8 years of real-world experience^{5,6,11}

The most frequently reported adverse reactions are upper respiratory tract infections (17.1%) (most frequently nasopharyngitis, rhinitis).^{5,6}

Cosentyx licensed indications in rheumatology: Cosentyx is indicated for the treatment of active psoriatic arthritis in adult patients (alone or in combination with methotrexate) when the response to previous disease-modifying anti-rheumatic drug therapy has been inadequate; active ankylosing spondylitis in adults who have responded inadequately to conventional therapy; active non-radiographic axial spondyloarthritis with objective signs of inflammation as indicated by elevated C-reactive protein and/or magnetic resonance imaging evidence in adults who have responded inadequately to non-steroidal anti-inflammatory drugs; moderate to severe plaque psoriasis in children and adolescents from the age of 6 years, and adults who are candidates for systemic therapy; active enthesitis-related arthritis in patients 6 years and older (alone or in combination with methotrexate) whose disease has responded inadequately to, or who cannot tolerate conventional therapy; active juvenile psoriatic arthritis in patients 6 years or older (alone or in combination with methotrexate) whose disease has responded inadequately to, or who cannot tolerate, conventional therapy.^{5,6}

ULTIMATE (N=166), a multicentre, randomised, double-blind, placebo-controlled, 52-week Phase III trial in patients with PsA. Patients were randomly assigned to receive either weekly subcutaneous Cosentyx (300 mg or 150 mg according to the severity of psoriasis) or placebo followed by 4-weekly dosing thereafter. The primary outcome of mean change in the ultrasound GLOESS from baseline to Week 12 was met (-9 vs -6; p=0.004).^{2,3}

MATURE (N=122), a 52-week, multicentre, double-blind, randomised, placebo-controlled, Phase III trial in patients with PsO. Eligible patients were randomised to Cosentyx 300 mg or placebo. The co-primary endpoints were PASI75 and IGA mod 2011 0/1 responses at Week 12. The study met the co-primary endpoints: PASI75 and IGA mod 2011 0/1 response at Week 12 were met for Cosentyx 300 mg vs placebo (95% vs 10% and 76% vs 8% respectively, p<0.0001).⁴

MAXIMISE (N=498) a double blind, placebo-controlled, multicentre, Phase IIIb study in patients with PsA. Patients were randomised in a 1:1:1 ratio to receive Cosentyx 300 mg, 150 mg or placebo. The primary endpoint of the proportion of patients achieving and ASAS20 response with Cosentyx 300 mg at Week 12 vs placebo was met (63% vs 31% respectively, p<0.0001).¹

ACR, American College of Rheumatology; AI, auto-injector; ASAS, Assessment of SpondyloArthritis International Society; BASDAI, Bath; ankylosing spondylitis disease activity index; EULAR, European Alliance of Associations for Rheumatology; GLOESS, Global EULAR and OMERACT synovitis score; IGA mod 2011 0/1, investigator global assessment modified 2011 0/1; OMERACT, outcome measures in rheumatology; PASI, psoriasis area and severity index; PsA, psoriatic arthritis; PsO, plaque psoriasis.

References: 1. Baraliakos X, et al. *RMD open* 2019;5:e001005; 2. Conaghan PG, et al. Poster 253. *Rheumatology* 2022;61(Suppl1). DOI:10.1093/rheumatology/keac133.252; 3. D'Agostino MA, et al. *Rheumatology* 2022;61:1867-1876; 4. Sigurgeirsson B, et al. *Dermatol Ther* 2022;35(3):e15285; 5. Cosentyx[®] (secukinumab) GB Summary of Product Characteristics; 6. Cosentyx[®] (secukinumab) NI Summary of Product Characteristics; 7. Lynde CW, et al. *J Am Acad Dermatol* 2014;71(1):141-150; 8. Fala L. *Am Health Drug Benefits* 2016;9(Special Feature):60-63; 9. Schön M & Erpenbeck L. *Front Immunol* 2018;9:1323; 10. Gorelick J, et al. *Practical Dermatol* 2016;12:35-50; 11. European Medicines Agency. European public assessment report. Medicine overview. Cosentyx (secukinumab). Available at: https://www.ema.europa.eu/en/documents/overview/cosentyx-epar-medicine-overview_en.pdf [Accessed May 2024].

Prescribing information, adverse event reporting and full indication can be found on the next page.

Cosentyx® (secukinumab) Great Britain Prescribing Information.

Please refer to the Summary of Product Characteristics (SmPC) before prescribing.

Indications: Treatment of: moderate to severe plaque psoriasis in adults, children and adolescents from the age of 6 years who are candidates for systemic therapy; active psoriatic arthritis in adults (alone or in combination with methotrexate) who have responded inadequately to disease-modifying anti-rheumatic drug therapy; active ankylosing spondylitis in adults who have responded inadequately to conventional therapy; active non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI) evidence in adults who have responded inadequately to non-steroidal anti-inflammatory drugs; active enthesitis-related arthritis and juvenile psoriatic arthritis in patients 6 years and older (alone or in combination with methotrexate) whose disease has responded inadequately to, or who cannot tolerate, conventional therapy; active moderate to severe hidradenitis suppurativa (acne inversa) in adults with an inadequate response to conventional systemic HS therapy. **Presentations:** Cosentyx 75 mg solution for injection in pre-filled syringe; Cosentyx 150 mg solution for injection in pre-filled syringe; Cosentyx 150 mg solution for injection in pre-filled pen; Cosentyx 300 mg solution for injection in pre-filled pen. **Dosage & Administration:** Administered by subcutaneous injection at weeks 0, 1, 2, 3 and 4, followed by monthly maintenance dosing. Consider discontinuation if no response after 16 weeks of treatment. Each 75 mg dose is given as one injection of 75 mg. Each 150 mg dose is given as one injection of 150 mg. Each 300 mg dose is given as two injections of 150 mg or one injection of 300 mg. If possible avoid areas of the skin showing psoriasis. **Plaque Psoriasis:** Adult recommended dose is 300 mg. Based on clinical response, a maintenance dose of 300 mg every 2 weeks may provide additional benefit for patients with a body weight of 90 kg or higher. Adolescents and children from the age of 6 years: if weight \geq 50 kg, recommended dose is 150 mg (may be increased to 300 mg as some patients may derive additional benefit from the higher dose). If weight < 50 kg, recommended dose is 75 mg. **Psoriatic Arthritis:** For patients with concomitant moderate to severe plaque psoriasis see adult plaque psoriasis recommendation. For patients who are anti-TNF α inadequate responders, the recommended dose is 300 mg, 150 mg in other patients. Can be increased to 300 mg based on clinical response. **Ankylosing Spondylitis:** Recommended dose 150 mg. Can be increased to 300 mg based on clinical response. **nr-axSpA:** Recommended dose 150 mg. **Enthesitis-related arthritis and juvenile psoriatic arthritis:** From the age of 6 years, if weight \geq 50 kg, recommended dose is 150 mg. If weight < 50 kg, recommended dose is 75 mg. **Hidradenitis suppurativa:**

Cosentyx® (secukinumab) Northern Ireland Prescribing Information.

Please refer to the Summary of Product Characteristics (SmPC) before prescribing.

Indications: Treatment of: moderate to severe plaque psoriasis in adults, children and adolescents from the age of 6 years who are candidates for systemic therapy; active psoriatic arthritis in adults (alone or in combination with methotrexate) who have responded inadequately to disease-modifying anti-rheumatic drug therapy; active ankylosing spondylitis in adults who have responded inadequately to conventional therapy; active non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation as indicated by elevated C-reactive protein (CRP) and/or magnetic resonance imaging (MRI) evidence in adults who have responded inadequately to non-steroidal anti-inflammatory drugs; active enthesitis-related arthritis and juvenile psoriatic arthritis in patients 6 years and older (alone or in combination with methotrexate) whose disease has responded inadequately to, or who cannot tolerate, conventional therapy; active moderate to severe hidradenitis suppurativa (acne inversa) in adults with an inadequate response to conventional systemic HS therapy. **Presentations:** Cosentyx 150 mg solution for injection in pre-filled pen; Cosentyx 300 mg solution for injection in pre-filled pen. **Dosage & Administration:** Administered by subcutaneous injection at weeks 0, 1, 2, 3 and 4, followed by monthly maintenance dosing. Consider discontinuation if no response after 16 weeks of treatment. Each 150 mg dose is given as one injection of 150 mg. Each 300 mg dose is given as two injections of 150 mg or one injection of 300 mg. If possible avoid areas of the skin showing psoriasis. **Plaque Psoriasis:** Adult recommended dose is 300 mg monthly. Based on clinical response, a maintenance dose of 300 mg every 2 weeks may provide additional benefit for patients with a body weight of 90 kg or higher. Adolescents and children from the age of 6 years: if weight \geq 50 kg, recommended dose is 150 mg (may be increased to 300 mg as some patients may derive additional benefit from the higher dose). If weight < 50 kg, recommended dose is 75 mg. However, 150mg solution for injection in pre-filled pen is not indicated for administration of this dose and no suitable alternative formulation is available. **Psoriatic Arthritis:** For patients with concomitant moderate to severe plaque psoriasis see adult plaque psoriasis recommendation. For patients who are anti-TNF α inadequate responders, the recommended dose is 300 mg, 150 mg in other patients. Can be increased to 300 mg based on clinical response. **Ankylosing Spondylitis:** Recommended dose 150 mg. Can be increased to 300 mg based on clinical response. **nr-axSpA:** Recommended dose 150 mg. **Enthesitis-related arthritis and juvenile psoriatic arthritis:** From the age of 6 years, if weight \geq 50 kg, recommended dose is 150 mg. If weight < 50 kg, recommended dose

is 75 mg. However, 150mg solution for injection in pre-filled pen is not indicated for administration of this dose and no suitable alternative formulation is available. **Hidradenitis suppurativa:** Recommended dose is 300 mg monthly. Based on clinical response, the maintenance dose can be increased to 300 mg every 2 weeks. **Contraindications:** Hypersensitivity to the active substance or excipients. Clinically important, active infection. **Warnings & Precautions:** **Infections:** Potential to increase risk of infections; serious infections have been observed. Caution in patients with chronic infection or history of recurrent infection. Advise patients to seek medical advice if signs/symptoms of infection occur. Monitor patients with serious infection closely and do not administer Cosentyx until the infection resolves. Non-serious mucocutaneous candida infections were more frequently reported for secukinumab than placebo in the psoriasis clinical studies. Should not be given to patients with active tuberculosis (TB). Consider anti-tuberculosis therapy before starting Cosentyx in patients with latent TB. **Inflammatory bowel disease (including Crohn's disease and ulcerative colitis):** New cases or exacerbations of inflammatory bowel disease have been reported with secukinumab. Secukinumab, is not recommended in patients with inflammatory bowel disease. If a patient develops signs and symptoms of inflammatory bowel disease or experiences an exacerbation of pre-existing inflammatory bowel disease, secukinumab should be discontinued and appropriate medical management should be initiated. **Hypersensitivity reactions:** Rare cases of anaphylactic reactions have been observed. If an anaphylactic or serious allergic reactions occur, discontinue immediately and initiate appropriate therapy. **Vaccinations:** Do not give live vaccines concurrently with Cosentyx; inactivated or non-live vaccinations may be given. Paediatric patients should receive all age appropriate immunisations before treatment with Cosentyx. **Latex-Sensitive Individuals:** The removable needle cap of the 75mg and 150 mg pre-filled syringe and 150mg pre-filled pen contains a derivative of natural rubber latex. **Concomitant immunosuppressive therapy:** Combination with immunosuppressants, including biologics, or phototherapy has not been evaluated in psoriasis studies. Cosentyx was given concomitantly with methotrexate, sulfasalazine and/or corticosteroids in arthritis studies. Caution when considering concomitant use of other immunosuppressants. **Interactions:** Live vaccines should not be given concurrently with secukinumab. No interaction between Cosentyx and midazolam (CYP3A4 substrate) seen in adult psoriasis study. No interaction between Cosentyx and methotrexate and/or corticosteroids seen in arthritis studies. **Fertility, pregnancy and lactation:** **Women of childbearing potential:** Use an effective method of contraception during and for at least 20 weeks after treatment. **Pregnancy:** Preferably avoid use of Cosentyx in pregnancy. **Breast feeding:** It is not known if secukinumab is excreted in human breast milk. A clinical decision should be made on continuation of breast feeding during Cosentyx treatment (and up to 20 weeks after discontinuation) based on benefit of breast feeding to the child and benefit of Cosentyx therapy to the

is 75 mg. However, 150mg solution for injection in pre-filled pen is not indicated for administration of this dose and no suitable alternative formulation is available. **Hidradenitis suppurativa:** Recommended dose is 300 mg monthly. Based on clinical response, the maintenance dose can be increased to 300 mg every 2 weeks. **Contraindications:** Hypersensitivity to the active substance or excipients. Clinically important, active infection. **Warnings & Precautions:** **Infections:** Potential to increase risk of infections; serious infections have been observed. Caution in patients with chronic infection or history of recurrent infection. Advise patients to seek medical advice if signs/symptoms of infection occur. Monitor patients with serious infection closely and do not administer Cosentyx until the infection resolves. Non-serious mucocutaneous candida infections were more frequently reported for secukinumab than placebo in the psoriasis clinical studies. Should not be given to patients with active tuberculosis (TB). Consider anti-tuberculosis therapy before starting Cosentyx in patients with latent TB. **Inflammatory bowel disease (including Crohn's disease and ulcerative colitis):** New cases or exacerbations of inflammatory bowel disease have been reported with secukinumab. Secukinumab, is not recommended in patients with inflammatory bowel disease. If a patient develops signs and symptoms of inflammatory bowel disease or experiences an exacerbation of pre-existing inflammatory bowel disease, secukinumab should be discontinued and appropriate medical management should be initiated. **Hypersensitivity reactions:** Rare cases of anaphylactic reactions have been observed. If an anaphylactic or serious allergic reactions occur, discontinue immediately and initiate appropriate therapy. **Vaccinations:** Do not give live vaccines concurrently with Cosentyx; inactivated or non-live vaccinations may be given. Paediatric patients should receive all age appropriate immunisations before treatment with Cosentyx. **Latex-Sensitive Individuals:** The removable needle cap of the 150mg pre-filled pen contains a derivative of natural rubber latex. **Concomitant immunosuppressive therapy:** Combination with immunosuppressants, including biologics, or phototherapy has not been evaluated in psoriasis studies. Cosentyx was given concomitantly with methotrexate, sulfasalazine and/or corticosteroids in arthritis studies. Caution when considering concomitant use of other immunosuppressants. **Interactions:** Live vaccines should not be given concurrently with secukinumab. No interaction between Cosentyx and midazolam (CYP3A4 substrate) seen in adult psoriasis study. No interaction between Cosentyx and methotrexate and/or corticosteroids seen in arthritis studies. **Fertility, pregnancy and lactation:** **Women of childbearing potential:** Use an effective method of contraception during and for at least 20 weeks after treatment. **Pregnancy:** Preferably avoid use of Cosentyx in pregnancy. **Breast feeding:** It is not known if secukinumab is excreted in human breast milk. A clinical decision should be made on

continuation of breast feeding during Cosentyx treatment (and up to 20 weeks after discontinuation) based on benefit of breast feeding to the child and benefit of Cosentyx therapy to the woman. **Fertility:** Effect on human fertility not evaluated. **Adverse Reactions:** **Very Common** (\geq 1/10): Upper respiratory tract infection. **Common** (\geq 1/100 to <1/10): Oral herpes, headache, rhinorrhoea, diarrhoea, nausea, fatigue. **Uncommon** (\geq 1/1,000 to <1/100): Oral candidiasis, lower respiratory tract infections, neutropenia, inflammatory bowel disease. **Rare** (\geq 1/10,000 to <1/1,000): anaphylactic reactions, exfoliative dermatitis (psoriasis patients), hypersensitivity vasculitis. **Not known:** Mucosal and cutaneous candidiasis (including oesophageal candidiasis). **Infections:** Most infections were non-serious and mild to moderate upper respiratory tract infections, e.g. nasopharyngitis, and did not necessitate treatment discontinuation. There was an increase in mucosal and cutaneous (including oesophageal) candidiasis, but cases were mild or moderate in severity, non-serious, responsive to standard treatment and did not necessitate treatment discontinuation. Serious infections occurred in a small proportion of patients (0.015 serious infections reported per patient year of follow up). **Neutropenia:** Neutropenia was more frequent with secukinumab than placebo, but most cases were mild, transient and reversible. Rare cases of neutropenia CTCAE Grade 4 were reported. **Hypersensitivity reactions:** Urticaria and rare cases of anaphylactic reactions were seen. **Immunogenicity:** Less than 1% of patients treated with Cosentyx developed antibodies to secukinumab up to 52 weeks of treatment. **Other Adverse Effects:** The list of adverse events is not exhaustive, please consult the SmPC for a detailed listing of all adverse events before prescribing. **Legal Category:** POM. **MA Number & List Price:** PLGB 00101/1205 – 75 mg pre-filled syringe x 1 - £304.70; PLGB 00101/1029 - 150 mg pre-filled pen x2 £1,218.78; PLGB 00101/1030 - 150 mg pre-filled syringe x2 £1,218.78; PLGB 00101/1198 – 300 mg pre-filled pen x1 £1218.78. **PI Last Revised:** June 2023. Full prescribing information, (SmPC) is available from: Novartis Pharmaceuticals UK Limited, 2nd Floor, The WestWorks Building, White City Place, 195 Wood Lane, London, W12 7FQ. Telephone: (01276) 692255.

UK | 290802 | June 2023

Adverse Event Reporting:

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis via uk.patientsafety@novartis.com or online through the pharmacovigilance intake (PVI) tool at www.novartis.com/report. If you have a question about the product, please contact Medical Information on 01276 698370 or by email at medinfo.uk@novartis.com

continuation of breast feeding during Cosentyx treatment (and up to 20 weeks after discontinuation) based on benefit of breast feeding to the child and benefit of Cosentyx therapy to the woman. **Fertility:** Effect on human fertility not evaluated. **Adverse Reactions:** **Very Common** (\geq 1/10): Upper respiratory tract infection. **Common** (\geq 1/100 to <1/10): Oral herpes, headache, rhinorrhoea, diarrhoea, nausea, fatigue. **Uncommon** (\geq 1/1,000 to <1/100): Oral candidiasis, lower respiratory tract infections, neutropenia, inflammatory bowel disease. **Rare** (\geq 1/10,000 to <1/1,000): anaphylactic reactions, exfoliative dermatitis (psoriasis patients), hypersensitivity vasculitis. **Not known:** Mucosal and cutaneous candidiasis (including oesophageal candidiasis). **Infections:** Most infections were non-serious and mild to moderate upper respiratory tract infections, e.g. nasopharyngitis, and did not necessitate treatment discontinuation. There was an increase in mucosal and cutaneous (including oesophageal) candidiasis, but cases were mild or moderate in severity, non-serious, responsive to standard treatment and did not necessitate treatment discontinuation. Serious infections occurred in a small proportion of patients (0.015 serious infections reported per patient year of follow up). **Neutropenia:** Neutropenia was more frequent with secukinumab than placebo, but most cases were mild, transient and reversible. Rare cases of neutropenia CTCAE Grade 4 were reported. **Hypersensitivity reactions:** Urticaria and rare cases of anaphylactic reactions were seen. **Immunogenicity:** Less than 1% of patients treated with Cosentyx developed antibodies to secukinumab up to 52 weeks of treatment. **Other Adverse Effects:** The list of adverse events is not exhaustive, please consult the SmPC for a detailed listing of all adverse events before prescribing. **Legal Category:** POM. **MA Number & List Price:** EU/1/14/980/005 - 150 mg pre-filled pen x2 £1,218.78; EU/1/14/980/010 - 300 mg pre-filled pen x1 £1218.78. **PI Last Revised:** May 2023. Full prescribing information, (SmPC) is available from: Novartis Pharmaceuticals UK Limited, 2nd Floor, The WestWorks Building, White City Place, 195 Wood Lane, London, W12 7FQ. Telephone: (01276) 692255.

UK | 284832 | May 2023

Adverse Event Reporting:

Adverse events should be reported. Reporting forms and information can be found at www.mhra.gov.uk/yellowcard. Adverse events should also be reported to Novartis via uk.patientsafety@novartis.com or online through the pharmacovigilance intake (PVI) tool at www.novartis.com/report. If you have a question about the product, please contact Medical Information on 01276 698370 or by email at medinfo.uk@novartis.com